If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> UROLOGY<br /> OM Pharma/Vifor Pharma supplement • emjreviews.com<br /> INSIDE<br /> Summary of Selected Presentations<br /> OM Pharma/Vifor Pharma URO-VAXOM® Summit<br /> Buenos Aires, Argentina, 2014<br /> CONTENTS<br /> Narrative Summary of Selected Presentations given at the<br /> OM Pharma/Vifor Pharma URO-VAXOM® Summit, held in<br /> Buenos Aires, Argentina, on 26th–27th April 2014<br /> RECURRENT URINARY TRACT INFECTIONS: ANTIBIOTIC RESISTANCE AND GUIDELINES...... 3<br /> • Florian M.E. Wagenlehner, Matteo Bassetti, José Tirán-Saucedo, Kurt G. Naber<br /> INTRODUCTION TO THE BURDEN OF RECURRENT CYSTITIS AND RATIONALE FOR<br /> PREVENTION........................................................................................................................................... 14<br /> • Enrique Patricio Ubertazzi, Björn Wullt, José Tirán-Saucedo<br /> RECURRENT URINARY TRACT INFECTIONS: CAN IMMUNOACTIVE PROPHY<a title="EMJ Urol. 2014 Suppl 2 page 1" href="http://viewer.zmags.com/publication/68fc50e2?page=1"> UROLOGY OM Pharma/Vifor Pharma supplement • emjre</a> <a title="EMJ Urol. 2014 Suppl 2 page 2" href="http://viewer.zmags.com/publication/68fc50e2?page=2"> CONTENTS Narrative Summary of Select</a> <a title="EMJ Urol. 2014 Suppl 2 page 3" href="http://viewer.zmags.com/publication/68fc50e2?page=3"> RECURRENT URINARY TRACT INFECTIONS: ANTIBIOTIC </a> <a title="EMJ Urol. 2014 Suppl 2 page 4" href="http://viewer.zmags.com/publication/68fc50e2?page=4"> by expansion of these clones which can, in turn, </a> <a title="EMJ Urol. 2014 Suppl 2 page 5" href="http://viewer.zmags.com/publication/68fc50e2?page=5"> The Globalisation of ABR It may be that the true </a> <a title="EMJ Urol. 2014 Suppl 2 page 6" href="http://viewer.zmags.com/publication/68fc50e2?page=6"> ARESC study, no other organism was implicated sig</a> <a title="EMJ Urol. 2014 Suppl 2 page 7" href="http://viewer.zmags.com/publication/68fc50e2?page=7"> 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Nort</a> <a title="EMJ Urol. 2014 Suppl 2 page 8" href="http://viewer.zmags.com/publication/68fc50e2?page=8"> healthcare structures present across the globe. E</a> <a title="EMJ Urol. 2014 Suppl 2 page 9" href="http://viewer.zmags.com/publication/68fc50e2?page=9"> patients with UC: non-pregnant pre-menopausal</a> <a title="EMJ Urol. 2014 Suppl 2 page 10" href="http://viewer.zmags.com/publication/68fc50e2?page=10"> Care must be taken when considering antibiotic us</a> <a title="EMJ Urol. 2014 Suppl 2 page 11" href="http://viewer.zmags.com/publication/68fc50e2?page=11"> In Mexico there are high rates of resistance to T</a> <a title="EMJ Urol. 2014 Suppl 2 page 12" href="http://viewer.zmags.com/publication/68fc50e2?page=12"> Local knowledge of resistance rates is key and th</a> <a title="EMJ Urol. 2014 Suppl 2 page 13" href="http://viewer.zmags.com/publication/68fc50e2?page=13"> Chemother J. 2011;20:158-68. 33. Bjerklund Johans</a> <a title="EMJ Urol. 2014 Suppl 2 page 14" href="http://viewer.zmags.com/publication/68fc50e2?page=14"> INTRODUCTION TO THE BURDEN OF RECURRENT CYSTI</a> <a title="EMJ Urol. 2014 Suppl 2 page 15" href="http://viewer.zmags.com/publication/68fc50e2?page=15"> an innovative online patient-focused methodology </a> <a title="EMJ Urol. 2014 Suppl 2 page 16" href="http://viewer.zmags.com/publication/68fc50e2?page=16"> in% 100 90 80 70 60 50 40 30 20 10 0 p<0.0</a> <a title="EMJ Urol. 2014 Suppl 2 page 17" href="http://viewer.zmags.com/publication/68fc50e2?page=17"> other therapies. Respondents from Germany</a> <a title="EMJ Urol. 2014 Suppl 2 page 18" href="http://viewer.zmags.com/publication/68fc50e2?page=18"> The first study was conducted in 38 spinal cord in</a> <a title="EMJ Urol. 2014 Suppl 2 page 19" href="http://viewer.zmags.com/publication/68fc50e2?page=19"> measure due to putative benefits conferred b</a> <a title="EMJ Urol. 2014 Suppl 2 page 20" href="http://viewer.zmags.com/publication/68fc50e2?page=20"> women, and spinal cord injury patients;31–34 thre</a> <a title="EMJ Urol. 2014 Suppl 2 page 21" href="http://viewer.zmags.com/publication/68fc50e2?page=21"> 1993;150(3):917-21. 27. Magasi P et al. Uro-</a> <a title="EMJ Urol. 2014 Suppl 2 page 22" href="http://viewer.zmags.com/publication/68fc50e2?page=22"> RECURRENT URINARY TRACT INFECTIONS: CAN IMMUNOAC</a> <a title="EMJ Urol. 2014 Suppl 2 page 23" href="http://viewer.zmags.com/publication/68fc50e2?page=23"> and granulocytes.4 Perhaps the most well-known PA</a> <a title="EMJ Urol. 2014 Suppl 2 page 24" href="http://viewer.zmags.com/publication/68fc50e2?page=24"> localised to the urogenital tract following repea</a> <a title="EMJ Urol. 2014 Suppl 2 page 25" href="http://viewer.zmags.com/publication/68fc50e2?page=25"> revealing novel efficacy or safety-related data d</a> <a title="EMJ Urol. 2014 Suppl 2 page 26" href="http://viewer.zmags.com/publication/68fc50e2?page=26"> The final meta-analysis included a number of other</a> <a title="EMJ Urol. 2014 Suppl 2 page 27" href="http://viewer.zmags.com/publication/68fc50e2?page=27"> dosing for each of the last 3 months. Subjects we</a> <a title="EMJ Urol. 2014 Suppl 2 page 28" href="http://viewer.zmags.com/publication/68fc50e2?page=28"> properties of a bacterial extract from Esche</a> <a title="EMJ Urol. 2014 Suppl 2 page 29" href="http://viewer.zmags.com/publication/68fc50e2?page=29"> URINARY TRACT INFECTION IN SPECIFIC POPULATIONS </a> <a title="EMJ Urol. 2014 Suppl 2 page 30" href="http://viewer.zmags.com/publication/68fc50e2?page=30"> neonatal death.3,4 The potential for serious clin</a> <a title="EMJ Urol. 2014 Suppl 2 page 31" href="http://viewer.zmags.com/publication/68fc50e2?page=31"> The oral immunostimulant prophylactic OM-89 h</a> <a title="EMJ Urol. 2014 Suppl 2 page 32" href="http://viewer.zmags.com/publication/68fc50e2?page=32"> delay resolution if not addressed.24 Other common</a> <a title="EMJ Urol. 2014 Suppl 2 page 33" href="http://viewer.zmags.com/publication/68fc50e2?page=33"> treat them, expose women to both categories of ri</a> <a title="EMJ Urol. 2014 Suppl 2 page 34" href="http://viewer.zmags.com/publication/68fc50e2?page=34"> the age of 20 years and estimated prevalence at a</a> <a title="EMJ Urol. 2014 Suppl 2 page 35" href="http://viewer.zmags.com/publication/68fc50e2?page=35"> of asymptomatic CAB at 14 days in a closed system</a> <a title="EMJ Urol. 2014 Suppl 2 page 36" href="http://viewer.zmags.com/publication/68fc50e2?page=36"> Current prophylactic measures are lacking in</a> <a title="EMJ Urol. 2014 Suppl 2 page 37" href="http://viewer.zmags.com/publication/68fc50e2?page=37"> of comparability between trials due to variabilit</a> <a title="EMJ Urol. 2014 Suppl 2 page 38" href="http://viewer.zmags.com/publication/68fc50e2?page=38"> Summary Despite limited epidemiological data, it </a> <a title="EMJ Urol. 2014 Suppl 2 page 39" href="http://viewer.zmags.com/publication/68fc50e2?page=39"> Syst Rev. 2001;(4):CD001534. 27. Kizilca O et </a> <a title="EMJ Urol. 2014 Suppl 2 page 40" href="http://viewer.zmags.com/publication/68fc50e2?page=40"> 73. Hazan Z et al. Effective prevention of microb</a>